ABSTRACT
Gynecological cancers (ovarian, uterine, cervical, vulval, and vaginal) affect 17,000 women per year in the United Kingdom and many women still present with advanced disease with little prospect of cure. The optimal management of gynecological malignancies is increasingly complex and involves a multidisciplinary approach. There remains a significant risk of recurrence and resistance to therapy despite advances in surgical, radio, and chemotherapeutic strategies. However, over recent years, there have been improvements in our understanding of the biology of gynecological cancers and in the design of molecularly targeted therapies. This chapter summarizes the medical management of gynecological cancers and, in particular, the roles of chemotherapy and targeted agents.
